Ranok Initiates China Phase 1 Trial for CHAMP® BRD4 Degrader RNK05047

Ranok Therapeutics, a biopharmaceutical firm specializing in targeted protein degradation for cancer treatment, has commenced a Phase 1 clinical trial in China for RNK05047, its first protein degrader candidate. This follows a similar Phase 1 trial in the U.S. and aims to assess the safety, tolerability, and pharmacological properties of RNK05047 in Chinese patients with advanced cancers. The company expects to release preliminary data from both trials by the end of 2024.
RNK05047, developed using Ranok's CHAMP® technology, is a BRD4-selective protein degrader that is currently in clinical testing in China. The compound is designed to preferentially degrade BRD4 protein in tumors, which may enhance safety and efficacy. Weiwen Ying, Ranok's CEO, highlighted the importance of extending the clinical study to an Asian population for valuable insights.
Ning Li, a leading cancer expert in China and the principal investigator for the study, emphasized the significance of BRD4 as a therapeutic target for various cancers. The study is being conducted at the National Cancer Center/Cancer Hospital, a leading institution in China for cancer diagnosis and treatment.
Further details on the trial are available at www.chinadrugtrials.org.cn (CTR20233943) and www.clinicaltrials.gov (NCT05487170).
Ranok's CHAMP® platform leverages the cellular chaperone network for protein degradation, offering advantages such as resistance to drug resistance mechanisms and improved safety due to selective targeting. RNK05047 is a novel, small-molecule degrader that targets BRD4, a key regulator in cancer, and is currently undergoing Phase 1 trials in the U.S. and China, with initial results anticipated by the end of 2024.
Ranok Therapeutics is a privately held company focused on developing innovative therapeutics through CHAMP®, targeting protein degradation for a range of diseases. The company's R&D team combines deep biological knowledge and chemistry expertise to advance CHAMP degraders for important disease targets, aiming to create transformative medicines for global patients. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!